This previous trial examined the utility of recombinant human granulocyte-macrophage colony stimulated factor (GM-CSF) for patients with acute lung injury based on pre-clinical data suggesting a protective effect of GM-CSF on alveolar macrophages and alveolar epithelial cells [11]. Here, CSF2 is linked to injury.